状细胞疾病中的内皮功能障碍:治疗策略
Aline Renata Pavan1, Barbara Terroni2, Jean Leandro Dos Santos2
1São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, Brazil; São Paulo State University (UNESP), Institute of Chemistry, Araraquara, Brazil.
Nitric oxide : biology and chemistry
|May 28, 2024
概括
状细胞贫血 (SCA) 涉及由于慢性炎症和氧化应激导致的内皮功能障碍. 针对氨酸-氧化物通路的新型小分子为SCA患者提供了有前途的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 血管生物学 血管生物学
- 分子医学是分子医学.
背景情况:
- 细胞贫血 (SCA) 是一种普遍存在的遗传血红蛋白病,其特征是血红蛋白异常 (HbS).
- 内皮功能障碍 (ED) 是SCA的一个关键特征,导致严重的临床并发症,如中风和肺高血压.
- 在SCA中ED的病理生理学涉及慢性炎症,氧化应激和改变的氧化 (NO) 生物可用性.
研究的目的:
- 审查目前治疗状细胞疾病 (SCD) 内皮功能障碍的策略.
- 探索小分子准氨酸-氧化物通路的潜力,以开发治疗方法.
- 为未来的药物设计提供见解,旨在减轻SCA中的ED.
主要方法:
- 关于SCD内皮质功能障碍现有文献的小综述.
- 分析导致ED的因素,包括与血液溶解相关的元素和氧化应激.
- 检查新兴的治疗点和小分子干预措施.
主要成果:
- 在SCA中的血液溶解导致氨酸和NO的可用性降低,粘附分子增加和氧化应激.
- 缺血-再输液损伤和酶活性进一步加剧了内皮功能障碍.
- 小分子正在研究它们的抗炎,抗氧化和NO路径调节特性.
结论:
- 用新的小分子准氨酸-氧化物通路显示出治疗SCA中ED的前景.
- 开发减少炎症和氧化应激的干预措施对于管理与SCA相关的并发症至关重要.
- 对这些治疗策略的进一步研究可以指导SCD有效药物的设计.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:23Antihypertensive Drugs: Vasodilators
505
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
505
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167